Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a routine place for health ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

Q2 2025 Management View Dan Dischner, Senior Vice President of Corporate Communications, highlighted that Amphastar delivered a solid performance in Q2 2025, underpinned by "the continued strength of ...

An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...